Ind-Swift Laboratories Ltd Q2 PAT Rises 3.5 Times to ₹31.03 Crore

Ind-Swift Laboratories Ltd reported Q2 FY27 PAT of ₹31.03 crore, 3.5 times higher year on year. Operating revenue rose 15.15% to ₹234.89 crore for the quarter ended September 30, 2026, while operating EBITDA reached ₹42.33 crore and the operating EBITDA margin expanded to 18.02%.

What did Ind-Swift Laboratories Ltd report for Q2 FY27?

Ind-Swift Laboratories Ltd reported a sharp improvement in profitability in the September quarter, supported by higher operating revenue and a lower employee and operating expense ratio. Q2 FY27 operating revenue was ₹234.89 crore, compared with ₹156.43 crore in the year-earlier period. Revenue was also 26.22% higher than ₹186.09 crore reported in the preceding quarter.

Operating EBITDA rose to ₹42.33 crore from ₹8.55 crore a year earlier, a 4.95-times increase. It was 27.04% above ₹33.32 crore in Q1 FY27. The operating EBITDA margin expanded by 1,256 basis points year on year to 18.02%, while the PAT margin stood at 13.21%, up 761 basis points from a year earlier.

Profit after tax was ₹31.03 crore, up 3.5 times year on year and 26.96% sequentially. The reported figures indicate that profit growth outpaced revenue growth during the quarter, reflecting the substantial increase in operating profitability.

How did costs and margins change during the quarter?

Ind-Swift Laboratories Ltd said employee and operating expenses declined to 45.15% of revenue in Q2 FY27, from 49.38% in the corresponding quarter of the previous year. This reduction of 423 basis points is important because it coincided with a significant expansion in the company’s EBITDA and PAT margins.

The operating EBITDA margin improved to 18.02%, compared with a much lower level in the year-earlier quarter, based on the disclosed 1,256-basis-point expansion. Sequentially, the margin increased by 11 basis points. The limited sequential change in margin came alongside a 26.22% rise in quarterly operating revenue and a 27.04% rise in operating EBITDA.

During the earnings call, Chief Financial Officer Gagan Agarwal said margins should rise to 19%-20% in the next quarter. He also indicated that the full-year blended margin should be above 19%. These are management comments and not reported financial results.

What was Ind-Swift Laboratories Ltd’s first-half performance?

Ind-Swift Laboratories Ltd reported H1 FY27 operating revenue of ₹420.97 crore, up 35.79% from ₹310.02 crore in H1 FY26. The first-half performance includes the September-quarter operating revenue of ₹234.89 crore and reflects a stronger revenue trajectory than the company recorded in the corresponding half of the prior year.

H1 operating EBITDA was ₹75.65 crore, more than 4.45 times the year-earlier level. The operating EBITDA margin was 17.97%, representing expansion of 1,554 basis points year on year. H1 PAT stood at ₹55.47 crore, up 3.29 times year on year, with a PAT margin of 13.18%.

Management reiterated its FY27 operating revenue growth guidance of more than 50%. Agarwal said the company was in a comfortable position to achieve its projected FY27 numbers. He also said FY28 guidance could be revised upward, though no revised target was disclosed in the available material.

What did management say about CDMO and product development?

Ind-Swift Laboratories Ltd said its CDMO revenue was about ₹65 crore in Q2 FY27, while revenue from own branded products was about ₹125 crore, according to Agarwal’s comments on the earnings call. These figures provide a broad view of the contribution from the company’s contract development and manufacturing activity and its own-brand portfolio.

On the development pipeline, management said 11 molecules under development are expected to be ready in FY28-29, with revenue expected from FY28-29. Two additional molecules are expected by FY29-30. Management also noted that registration for own-brand exports takes a minimum of about 1.5 years, with revenue generally beginning after that process.

The timeline matters for investors assessing the company’s future product-led revenue potential. However, the disclosed plans do not indicate any new molecule launch in FY28, and the stated timing remains dependent on development and registration processes.

How does the Q2 result affect investors and operations?

The Q2 result gives investors concrete evidence of stronger earnings conversion, as EBITDA and PAT increased faster than operating revenue. The lower expense-to-revenue ratio was a key reported factor behind the margin improvement. For the broader pharmaceutical manufacturing business, the disclosed CDMO and own-brand revenue mix also points to the importance of both business lines in the quarter.

The company made the audio recording of its November 4, 2026 earnings conference call available on its investor relations website. The call covered unaudited financial results for the quarter ended September 30, 2026. The company said the transcript would be shared with BSE Limited and the National Stock Exchange of India Limited and uploaded to its website in due course.

Conclusion

Ind-Swift Laboratories Ltd’s Q2 FY27 results showed higher operating revenue, substantial EBITDA growth and a 3.5-times year-on-year rise in PAT to ₹31.03 crore. The expansion in operating EBITDA margin to 18.02% and the decline in employee and operating expenses as a share of revenue were central to the quarter’s improved profitability.

Investors will next watch progress against management’s guidance for more than 50% FY27 revenue growth, its expectation of a 19%-20% margin in the next quarter, and the development timetable for 11 molecules expected to be ready in FY28-29. The earnings-call transcript, when released, may provide further detail on these operational milestones.